HSP90 inhibitors reversed hyperglycaemia in diabetic db/db mice and improved insulin sensitivity in insulin-resistant obese mice, further supporting the concept that the HSF1 pathway is a potentially viable anti-diabetic target. This evidence concerns the gene HSF1 and Hyperglycemia.